Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics. For more information, visit www.GeminiTherapeutics.com
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $42.5M
Founded date: 2015
Investors 5
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
| 30.07.2021 | Foresite C... | foresiteca... |
| - | OrbiMed | orbimed.co... |
| - | Atlas Vent... | atlasventu... |
| - | Lightstone... | lightstone... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.10.2017 | Series A | $42.5M | OrbiMed |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | David | Taylor | Director O... | linkedin.c... | - | t****r@gem... |
Mentions in press and media 9
| Date | Title | Description |
| 25.02.2021 | Biotech and healthtech firm Foresite Capital raises $969M new fund | The firm, which now has over $4 billion in assets under management, invests across all stages The biotech space has been growing in the last few years: according to Pitchbook, the space was on track to see more than $20 billion invested in ... |
| 15.10.2020 | It’s Raining Biotech SPACs! | SPACs are all the rage today. With the IPO market booming and public investors seeking better returns, blank check companies called “Special Purpose Acquisition Companies” (SPACs) have been fueling up their tanks and chasing down their merg... |
| 18.10.2017 | Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy | Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A, according to a news release. They also took part in the seed round last year. James McLaughlin, Gemini Therapeutics cofounder and CEO, said that the company focuses on pati... |
| 18.10.2017 | Term Sheet — Wednesday, October 18 | 5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop In the Valley, Jordan is also known for mentoring investors with non-tech backgrounds. One examples is Golden State W... |
| 17.10.2017 | Gemini Therapeutics Lands $42.5M | CAMBRIDGE, MA, Gemini Therapeutics today announced that it has completed a $42.5 million Series A financing to advance multiple programs into the clinic. >> Click here for more funding data on Gemini Therapeutics >> To expor... |
| 17.10.2017 | Gemini Therapeutics Raises $42.5M in Series A Financing | Gemini Therapeutics, a Cambridge, MA-based new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, completed a $42.5m Series A financing. The round was c... |
| 17.10.2017 | Gemini Therapeutics Announces $42.5 Million Series A | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, today announced that it has completed a... |
| 17.10.2017 | OrbiMed Leads $42.5M Series A for Gemini Therapeutics | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, today announced that it has completed a... |
| - | Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy | Fundus photo of macular scarring with normal blood vessels and optic nerve Gemini Therapeutics has closed a Series A round to advance its precision medicine therapy for dry age-related macular degeneration. The Cambridge, Massachusetts comp... |